You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Médicaments

La bibliothèque de médicaments donne accès à des renseignements sur plus de 100 médicaments anticancéreux commercialisés au Canada.

Trouvez plus d’information sur la sécurité  dans le document patient supplémentaire Comment prendre vos médicaments oraux contre le cancer de manière sécuritaire.

Displaying Drugs List

10 Items
Other Name(s): Erleada®
Funding:
Exceptional Access Program
  • apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
Updated
Jan 2020
Other Name(s): Tecentriq™
Funding:
New Drug Funding Program
  • Atezolizumab – Advanced or Metastatic Non-Small Cell Lung Cancer
Updated
Feb 2020
Updated
Feb 2020
Other Name(s): Tafinlar®
Funding:
Exceptional Access Program
  • daBRAfenib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
  • daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
  • daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Updated
Jan 2020
Other Name(s): Unituxin®
Funding:
High Cost Therapy Funding Program
  • Dinutuximab - Pediatric High-Risk Neuroblastoma
Updated
Jan 2020
Other Name(s): Imfinzi®
Funding:
New Drug Funding Program
  • Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation
Updated
Jan 2020
Other Name(s): Erwinase®
Funding:
New Drug Funding Program
  • Erwinia Asparaginase - Newly Diagnosed Pediatric ALL Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
  • Erwinia Asparaginase - Relapsed or Refractory Pediatric ALL Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia
Jan 2020
Other Name(s): Opdivo
Funding:
New Drug Funding Program
  • Nivolumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
  • Nivolumab - Advanced or Metastatic Non-Small Cell Lung Cancer
  • Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and No Prior mTOR Inhibitor
  • Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and Prior mTOR Inhibitor
  • Nivolumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck which is Platinum Resistant or Refractory
  • Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
  • Nivolumab plus Ipilimumab – Metastatic Renal Cell Carcinoma
  • Nivolumab - Relapsed Classical Hodgkin Lymphoma (cHL) Post-Autologous Stem Cell Transplant (ASCT)
  • Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma
Updated
Jan 2020
Other Name(s): Mekinist®
Funding:
Exceptional Access Program
  • trametinib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
  • trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
  • trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Updated
Jan 2020
Other Name(s): Herceptin®, Ogivri™, Trazimera™, Herzuma®
Funding:
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
  • Trastuzumab (Biosimilar) with First Line Docetaxel - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Vinorelbine - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Docetaxel - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Single Agent - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
  • Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Paclitaxel - Metastatic Breast Cancer
Updated
Feb 2020